Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innoviva (INVA) Assets: 2009-2025

Historic Assets for Innoviva (INVA) over the last 17 years, with Sep 2025 value amounting to $1.4 billion.

  • Innoviva's Assets rose 16.04% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 16.04%. This contributed to the annual value of $1.3 billion for FY2024, which is 4.63% up from last year.
  • Innoviva's Assets amounted to $1.4 billion in Q3 2025, which was up 7.16% from $1.3 billion recorded in Q2 2025.
  • Innoviva's 5-year Assets high stood at $1.4 billion for Q3 2025, and its period low was $789.1 million during Q2 2021.
  • For the 3-year period, Innoviva's Assets averaged around $1.2 billion, with its median value being $1.2 billion (2023).
  • As far as peak fluctuations go, Innoviva's Assets soared by 49.65% in 2022, and later declined by 10.51% in 2023.
  • Quarterly analysis of 5 years shows Innoviva's Assets stood at $926.4 million in 2021, then spiked by 32.93% to $1.2 billion in 2022, then rose by 0.98% to $1.2 billion in 2023, then rose by 4.63% to $1.3 billion in 2024, then rose by 16.04% to $1.4 billion in 2025.
  • Its Assets stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.